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Abstract
Vitamin D (VitD) supplementation has been advocated for cardiovascular risk reduction; however, supporting data are
sparse. The objective of this study was to determine whether VitD supplementation reduces cardiovascular risk. Subjects in
this prospective, randomized, double-blind, placebo-controlled trial of post-menopausal women with serum 25-
hydroxyvitamin D concentrations .10 and ,60 ng/mL were randomized to Vitamin D3 2500 IU or placebo, daily for
4 months. Primary endpoints were changes in brachial artery flow-mediated vasodilation (FMD), carotid-femoral pulse wave
velocity (PWV), and aortic augmentation index (AIx). The 114 subjects were mean (standard deviation) 63.9 (3.0) years old
with a 25-hydroxyvitamin D level of 31.3 (10.6) ng/mL. Low VitD (,30 ng/mL) was present in 47% and was associated with
higher body-mass index, systolic blood pressure, glucose, CRP, and lower FMD (all p,0.05). After 4 months, 25-
hydroxyvitamin D levels increased by 15.7 (9.3) ng/mL on vitamin D3 vs. 20.2 (6.1) ng/mL on placebo (p,0.001). There
were no significant differences between groups in changes in FMD (0.3 [3.4] vs. 0.3 [2.6] %, p=0.77), PWV (0.00 [1.06] vs.
0.05 [0.92] m/s, p=0.65), AIx (2.7 [6.3] vs. 0.9 [5.6] %, p=0.10), or CRP (0.3 [1.9] vs. 0.3 [4.2] mg/L, p=0.97). Multivariable
models showed no significant interactions between treatment group and low VitD status (,30 ng/mL) for changes in FMD
(p=0.65), PWV (p=0.93), AIx (p=0.97), or CRP (p=0.26).In conclusion, VitD supplementation did not improve endothelial
function, arterial stiffness, or inflammation. These observations do not support use of VitD supplementation to reduce
cardiovascular disease risk.
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Introduction
Although the definition of ‘‘low’’ vitamin D (VitD) status is
controversial, suboptimal VitD status is common worldwide [1].
Circulating 25-hydroxyvitamin D [25(OH)D] values ,30 ng/mL
are present in up to 57% of healthy US adults and in up to 50% of
postmenopausal women with osteoporosis [1,2]. A growing
literature suggests that low levels of VitD are associated with
increased total mortality [3] and cardiovascular disease (CVD) risk
[4–10]. VitD inadequacy has been linked to hypertension, insulin
resistance, metabolic syndrome, and congestive heart failure [4–8];
however, these associations mostly are derived from cross-sectional
and observational studies [4–8,11–13]. Low VitD status could
increase CVD risk by activating a pro-inflammatory cascade
resulting in endothelial dysfunction and increased arterial stiffness,
markers that contribute to hypertension and that are well-
recognized surrogates of CVD risk [14–17]. The limited number
of interventional studies that investigated the effects of VitD
supplementation on CVD risk have had mixed results [15,18–20].
To date, the only prospective randomized trial that evaluated the
effects of VitD supplementation on CVD events was the Women’s
Health Initiative [18]. No differences in CVD events or stroke over
7 years were observed in women treated with 400 IU daily of VitD
compared to placebo; however, this study has been criticized for
using an inadequate VitD dose [18]. Based on currently available
data, this dose of VitD only would be expected to raise 25(OH)D
levels by 2–3 ng/mL [21]. Moreover, the compliance in WHI only
was about 60%, so this small increase in 25(OH)D levels would
have even less of an observed effect [18]. Observational data
relating low VitD to CVD risk and other health conditions have led
some medical providers to prescribe VitD supplements for CVD
riskreduction,althoughdatasupportingthisinterventionaresparse.
The aim of this study was to determine if VitD supplementation
would improve flow-mediated vasodilation (FMD) of the brachial
artery, a measure of endothelial function, and 2 measures of arterial
stiffness, carotid-to-femoral pulse wave velocity (PWV) and aortic
augmentation index (AIx). These markers, and their changes, are
predictors of CVD risk [14,16,17].
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The protocol for this trial, CONSORT checklist, and Supple-
mental Table S1 are available as supporting information; see
Checklist S1, Protocol S1, and Table S1.
Ethics Statement
This study was approved by the University of Wisconsin Health
Sciences Institutional Review Board. It was conducted according
to the principles expressed in the Declaration of Helsinki. All
subjects provided written consent.
Study Design and Population
This was a prospective, randomized, double-blind, placebo-
controlled trial of post-menopausal women with serum 25(OH)D
concentrations between 10 and 60 ng/mL, as this range of vitamin
D levels was thought to be representative of the majority of the US
population, exclusive of those for whom withholding supplemen-
tation would not meet current standards of care. Participants were
healthy, community-dwelling, ambulatory women from Madison,
Wisconsin who were recruited between March 2009 and June
2010. Following informed consent, a screening evaluation of
demographic and laboratory assessments were performed. Qual-
ifying volunteers returned for a baseline visit. Endothelial function
Figure 1. CONSORT 2010 Flow Diagram. The first 34 subjects were part of a pilot study performed under NCT 00690417. The remainder of the
subjects were performed under NCT 01049048.
doi:10.1371/journal.pone.0036617.g001
Vitamin D and Cardiovascular Risk
PLoS ONE | www.plosone.org 2 May 2012 | Volume 7 | Issue 5 | e36617was evaluated by measuring brachial artery FMD in a core
ultrasound laboratory using a standardized protocol described
below [17,22,23]. Arterial stiffness was evaluated by determining
carotid-to-femoral PWV and AIx using applanation tonometry, as
described below [16,24]. Laboratory evaluations were performed
in a CLIA-approved lab and included fasting glucose, lipids,
calcium, parathyroid hormone, and high-sensitivity C-reactive
protein (CRP). Laboratory tests, FMD, and arterial stiffness studies
were performed prior to initiating therapy and after 4 months. All
measurements were performed in the morning after fasting for
$8 hours. The first 34 subjects were enrolled as part of a pilot
study that did not include arterial stiffness measurements. Arterial
tonometry measurements were recorded in the remainder of the
subjects after the techniques became available and recruitment
was demonstrated to be feasible (Figure 1).
Exclusion criteria included: history of CVD, serum calcium
.10.5 mg/dL, untreated primary hyperparathyroidism, history of
nephrolithiasis, hypercalciuria, malignancy, tuberculosis, sarcoid-
osis, Paget’s disease, malabsorption syndromes, estimated glomer-
ular filtration rate #25 mL/minute, use of medications that
interfere with vitamin D metabolism or affect bone turnover
(including hormone replacement therapy), use of active metabo-
lites of vitamin D within 6 months of screening, use of tanning
beds or salons, or unwillingness to utilize sunscreen during periods
of sun exposure of .15 minutes. All subjects agreed to avoid use
of cod-liver oil and non-study vitamin D supplementation and to
utilize sunscreen of SPF-15 or higher when sun exposure for
.15 minutes.
Randomization and Treatment Allocation
At the baseline study visit, volunteers were randomly assigned to
receive either 2500 IU of oral D3 in a cookie or an identical tasting
placebo cookie daily (D-Rich Foods, Inc., Manitowoc, Wisconsin).
Randomization was carried out in a 1:1 ratio without blocking
using computer-generated random numbers. One individual in the
Osteoporosis Research Center was assigned to randomize subjects
and package vitamin D/placebo cookies with labels; this individual
did not participate in recruitment, data collection, or analysis. All
others including volunteers, study staff, investigators, and data
Table 1. Baseline Subject Characteristics.
Placebo (N=57) Vitamin D (N=57)
P-value between treatment
groups
Age (years) 63.6 (3.1) 64.1 (3.0) 0.419
Years since menopause 13.4 (5.1) 14.1 (6.5) 0.921
Height (cm) 164.7 (5.1) 162.7 (6.8) 0.083
Weight (lbs) 151.0 (27.8) 157.7 (27.4) 0.114
Body-mass index (kg/m
2) 25.3 (5.1) 27.1 (4.7) 0.022
Total 25OH vitamin D (ng/mL) 32.3 (10.5) 30.3 (10.7) 0.353
Calcium (mg/dL) 9.4 (0.3) 9.4 (0.4) 0.862
Glucose (mg/dL) 97.4 (27.0) 97.5 (33.5) 0.978
Total cholesterol (mg/dL) 202.9 (36.2) 205.3 (31.0) 0.650
Triglycerides (mg/dL) 95.8 (47.4) 102.0 (50.2) 0.496
HDL cholesterol (mg/dL) 70.9 (20.3) 68.5 (18.5) 0.516
LDL cholesterol (mg/dL) 112.9 (32.9) 116.5 (28.0) 0.462
Total/HDL cholesterol ratio 3.1 (0.9) 3.2 (0.8) 0.563
C-reactive protein (mg/L) 1.9 (2.9) 2.5 (2.9) 0.287
Brachial artery diameter (cm) 0.36 (0.04) 0.36 (0.05) 0.664
Absolute FMD (cm) 0.016 (0.018) 0.018 (0.011) 0.521
Maximum Relative FMD (%) 4.57 (3.30) 5.05 (3.38) 0.452
Heart rate (bpm) 59.7 (9.6) 56.9 (7.0) 0.157
Brachial SBP (mmHg) 122.2 (11.8) 122.3 (13.1) 0.976
Brachial DBP (mmHg) 72.6 (7.1) 72.45 (7.6) 0.915
*Central SBP (mmHg) 115.6 (11.1) 116.7 (12.2) 0.660
*Central DBP (mmHg) 73.7 (7.1) 73.5 (7.7) 0.893
*Central pulse pressure (mmHg) 42.1(10.3) 43.3 (10.4) 0.581
*Pulse wave velocity (m/s) 8.0 (1.4) 7.8 (0.9) 0.426
*Augmentation index (%) 27.0 (7.2) 26.4 (6.5) 0.695
All values are means (standard deviations).
*Central blood pressures and stiffness measurements were obtained from 37 subjects in the placebo and 38 subjects in the vitamin D arms, respectively.
25OH Vitamin D=25-hydroxyvitamin D.
DBP = diastolic blood pressure.
FMD = flow-mediated dilation.
HDL = high density lipoprotein.
LDL = low density lipoprotein.
SBP = systolic blood pressure.
doi:10.1371/journal.pone.0036617.t001
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cross-over and all subjects were analyzed in an intention-to-treat
manner. Enrollment was complete following recruitment of the
pre-specified number of subjects.
Outcomes
The primary outcome measures were brachial artery FMD,
PWV, and AIx. Secondary outcomes included brachial and
central aortic blood pressures, serum glucose, fasting lipid, and
CRP levels. All tests were performed with subjects fasting between
7:00 and 11:00 AM.
Measurement of Endothelial Function and Arterial
Stiffness
Endothelial function was measured by ultrasound assessment of
brachial artery FMD [17,22,23]. Subjects were placed in a supine
position in a temperature-controlled room for 10 minutes before
imaging. A blood pressure cuff was placed on the widest part of the
proximal right forearm. Using an 8-MHz linear array vascular
ultrasound transducer and a state-of-the-art ultrasound system
(Acuson Sequoia 512, Siemens Medical Solutions, Issaquah,
Washington), the brachial artery was located above the elbow
and scanned longitudinally. After recording B-mode ultrasound
images of the brachial artery and spectral Doppler velocities, the
cuff was inflated to 250 mmHg for 5 minutes to induce reactive
hyperemia. Immediately after deflation, spectral Doppler images
were obtained to verify hyperemia. Brachial artery B-mode images
were obtained 60 and 90 seconds after cuff release. Studies were
recorded digitally; brachial artery diameters were measured in
triplicate with a digital border tracing tool (Access Point Web 3.0,
Freeland Systems, Westfield, Indiana). Studies were read in subject
pairs (baseline and 4 months), blinded to study treatment.
Reproducibility of measurements from this lab is excellent and
has been reported recently using the exact same techniques,
including during the time this study was being conducted [22,23].
Figure 2. Interactions Between the Effects of Treatment Group and Baseline Vitamin D Status on Outcome Variables. Abbreviations as
in Table 1.
doi:10.1371/journal.pone.0036617.g002
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SphygmoCor Px, AtCor Medical, Sydney, Australia) [16,24].
Tonometry recordings of the carotid and femoral arterial pulses
were taken when a reproducible signal with a clear upstroke was
obtained. The carotid-femoral PWV was determined by the
intersecting tangents method [16,24]. PWV (m/s) was calculated
as the distance-to-transit time ratio of the recorded pulse wave.
The time delay (seconds) from the electrocardiogram R-wave to
the foot of the arterial pulse waveform was measured at the
proximal (carotid) and distal (femoral) sites, based on an analysis of
10 seconds of stable tonometry tracings. The difference in the
proximal and distal delay was considered to be the carotid-femoral
transit time. The PWV distance was calculated as the difference in
the absolute distance between the suprasternal notch and the
carotid and femoral tonometry sites, respectively. AIx and central
aortic pressures were derived from radial tonometry using a
validated, generalized transfer function and calibrated using
oscillometric brachial artery blood pressures. All AIx measure-
ments were read independently and standardized to a heart rate of
75 bpm. An operator index greater than 85% was required for all
analyzed tracings. Reproducibility of these measurements from
this lab is excellent. For PWV, mean (standard deviation)
differences for repeated measurements is 0.035 (0.44) m/s with
an intra-class correlation coefficient of 0.91. For AIx and central
pulse pressure, mean differences are 0.02 (4.0)% and 0.20
(2.8) mmHg, respectively, with intra-class correlation coefficients
of 0.90 and 0.97, respectively.
Laboratory Analyses
Fasting serum chemistry, glucose, lipids, and CRP levels and
urinary calcium determinations were performed at General
Medical Laboratories (Madison, WI). CRP was measured by
nephelometry on a Siemens Vista analyzer using two control
products to assess the daily performance of the instrument. The
coefficient of variation was approximately 3.2%. Serum 25(OH)D
was determined using reverse phase high-performance liquid
chromatography as previously described [25,26].
Statistical Analysis and Sample Size
All analyses were conducted using STATA (Stata Statistical
Software: Release 11, College Station, TX). Between groups
comparisons were performed using two-tailed Student’s t-tests or
Mann-Whitney rank sum comparisons (for variables with non-
normal distributions). Pearson correlations were used to determine
associations with FMD. General linear models with 2 factors
including group and vitamin D status (.30 vs ,30 ng/mL), plus
their interaction, were used to determine independent associations.
All models were adjusted for body-mass index. Similar analyses
were performed for PWV, AIx, central aortic pressures, CRP, and
their changes. Bonferroni-adjusted p-values were reported for
these analyses. A priori power calculations estimated that a
minimum of 37 subjects in each arm would enable us to detect a
3% change in FMD with 80% power (alpha = 0.05). The sample
size was sufficient to detect an approximately 10% reduction in
PWV with a standard deviation of approximately 15%.
Results
Subject Characteristics
Of 133 potential subjects that were screened, 114 were eligible
(Figure 1). They were 63.9 (3.0) years old with a baseline 25(OH)D
level of 31.3 (10.6) ng/mL (Table 1). The median baseline
25(OH)D level was 30.3 ng/mL. These subjects were randomized
equally to each group; however, 2 subjects withdrew from each
group and 1 subject in the placebo group did not have arterial
stiffness measurements because of equipment failure. The final
data analysis included 55 subjects in the treatment group and 54
in the placebo group. PWV and AIx were measured in 38 and 37
consecutive subjects in the treatment and placebo groups,
respectively. Baseline characteristics were similar between groups
with the exception of the treatment group having a slightly higher
Table 2. Changes from Baseline in Placebo vs. Treatment Groups after 4 Months.
Change Placebo (N=55) Vitamin D (N=55)
P-value between treatment
groups
25(OH) vitamin D (ng/mL) 20.2 (6.1) 15.7 (9.3) ,0.001
Glucose (mg/dL) 3.1 (10.4) 2.5 (10.2) 0.551
Total/HDL cholesterol ratio 0.2 (0.4) 0.1 (0.4) ,0.001
C-reactive protein (mg/L) 0.3 (1.9) 0.3 (4.1) 0.971
Brachial artery diameter (cm) 0.003 (0.009) 0.002 (0.012) 0.812
Absolute FMD (cm) 0.001 (0.009) 0.001 (0.013) 0.729
Maximum relative FMD (%) 0.27 (2.64) 0.33 (3.43) 0.767
Heart rate (bpm) 2.0 (5.5) 1.7 (5.4) 0.780
Brachial SBP (mmHg) 22.5 (10.9) 20.3 (8.4) 0.402
Brachial DBP (mmHg) 20.4 (4.4) 20.7 (5.1) 0.599
Central SBP (mmHg) 22.1 (9.7) 20.3 (7.0) 0.428
Central DBP (mmHg) 20.5 (4.4) 20.7 (5.1) 0.844
Central pulse pressure (mmHg) 21.7 (8.9) 0.4 (8.6) 0.285
Pulse Wave Velocity (m/s) 0.00 (1.06) 0.05 (0.92) 0.652
Augmentation index (%) 0.9 (5.6) 2.7 (6.3) 0.096
All values are means (standard deviations).
*Central blood pressures and stiffness measurements were obtained from 37 subjects in the placebo and 38 subjects in the vitamin D arms, respectively.
Abbreviations as in Table 1.
doi:10.1371/journal.pone.0036617.t002
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2, p=0.022).
There were no differences between groups in baseline brachial
artery diameter (p=0.66) or other measures of CVD risk including
blood pressures, CRP, lipid profiles, or glucose level (all p.0.4)
(Table 1).
Effects of Treatment with VitD or Placebo
After 4 months, serum 25(OH)D increased by 15.7 (9.3) ng/mL
in the treatment group versus 20.2 (6.1) ng/mL in those taking
placebo (p,0.001). Despite improved VitD status, there were no
significant differences between groups in any of the pre-specified
outcomes including change in absolute FMD (0.001 [0.009] vs.
0.001 [0.013] cm p=0.729), maximum relative FMD (0.3 [3.4] vs.
0.3 [2.6] %, p=0.77), PWV (0.00 [1.06] vs. 0.05 [0.92] m/s,
p=0.65), AIx (2.7 [6.3] vs. 0.9 [5.6] %, p=0.10), or CRP (0.3
[1.9] vs. 0.3 [4.2] mg/L, p=0.97) (Table 2, Figure 2). Addition-
ally, there were no significant changes in central aortic or brachial
blood pressures (p.0.4). There was a small, statistically significant
increase in the total/high-density lipoprotein cholesterol ratio in
the placebo group compared to the treatment group (0.17 [0.36]
vs. 0.07 [0.39], p,0.001). No adverse events were reported.
Of those in the treatment group, 92% (N=51) had vitamin D
levels .30 ng/mL after 4 months of therapy. General linear
models showed no significant interaction between treatment group
and VitD status for changes in maximum relative FMD (p=0.65),
PWV (p=0.93), AIx (p=0.97), or CRP (p=0.26). No differences
were observed after adjustment for baseline body-mass index.
Low VitD status (,30 ng/mL) was present in 47% (n=54) of
subjects at baseline. Subjects with low VitD status had a mean
serum 25(OH)D level of 22.3 (standard deviation 5.26, range 9.1–
29.0) ng/mL; lower than those with normal VitD status who had a
mean serum 25(OH)D level of 39.7 (6.8, range 30.2–57.0) ng/mL.
Low VitD status was associated with higher body-mass index (28.2
[5.0] vs. 24.2 [4.2] kg/m
2,p ,0.001), brachial systolic blood
pressure (126.5 [13.3] vs. 118.6 [10.8] mmHg, p=0.004), glucose
(104.6 [42.3] vs. 90.8 [7.8] mg/dL, p=0.003), CRP (2.9 [3.4] vs
1.5 [2.1] mg/L, p=0.001), and lower maximum relative FMD
(4.1 [3.0] vs. 5.4 [3.6] %, p=0.043). After 4 months, those with
low baseline 25(OH)D levels had a nominally statistically
significant greater increase in maximum relative FMD than those
with 25(OH)D levels .30 ng/mL (1.1 [2.4] vs.20.5 [3.4]%,
p=0.002); however, this difference was independent of treatment
group (Figure 2, Table S1).
Discussion
We evaluated the effects of a higher dose of vitamin D
supplementation (2500 IU daily) than used in the Women’s Health
Initiative on several vascular parameters and markers of CVD risk.
In our study, treated subjects had circulating 25(OH)D levels that
increased, on average, by over 15 ng/mL and over 90% of treated
subjects achieved 25(OH)D levels .30 ng/mL. Nevertheless, we
did not observe an improvement in FMD or arterial stiffness
measures. Similarly, we did not observe differential improvements
in central or peripheral blood pressures or CRP levels between
treatment groups.
Our prospective, randomized, blinded study findings did not
show improvements in FMD or either arterial stiffness measure
after treatment with VitD. The few randomized controlled trials
that have evaluated the effects of vitamin D supplementation on
endothelial function or arterial stiffness have had mixed results in
regard to FMD [19,27,28], PWV [29], and AIx [30]; however,
those studies were notably smaller than our study and predom-
inantly were performed in adults with medical conditions such as
kidney disease and/or type II diabetes mellitus. Similarly, there
are mixed reports regarding changes in blood pressure following
VitD supplementation [15,20]. Despite higher blood pressures in
individuals with lower 25(OH)D levels, we found no change in
blood pressure after VitD supplementation, in agreement with the
largest of these trials [20]. Despite higher CRP levels in individuals
with lower 25(OH)D levels, we also found no change in CRP after
supplementation, a finding consistent with previous reports [30–
32]. The lack of an effect of VitD supplementation on these
markers of CVD risk was confirmed in our subgroup analyses
restricted to participants with low VitD status at baseline using
multivariable linear models which showed that treatment group
did not influence change in FMD, PWV, or AIx. Although
individuals with low VitD status at baseline had a small increase in
maximum relative FMD after 4 months, this increase was not
influenced by treatment group. Our results challenge the
hypothesis that VitD supplementation reduces CVD risk.
Vitamin D receptors are widely distributed throughout the body
and have been isolated from vascular endothelial cells and cardiac
myocytes [8]. Mechanistically it is conceivable that low VitD levels
could have deleterious CVD effects by dysregulation of systemic
calcium metabolism, as cardiac myocyte contraction depends on
calcium homeostasis and since coronary artery calcification is
predictive of CVD risk [6,8,9]. Also, VitD modulates lymphocytic
cytokine production [33], potentially affecting growth and
proliferation of vascular smooth muscle cells and cardiomyocytes
[34], stimulating vascular tissue anticoagulant activity [35], and
suppressing renin gene expression [36], which could lead to the
clinical manifestations of hypertension, coronary artery disease,
and congestive heart failure. However, mechanistic hypotheses do
not necessarily imply that supplementing individuals with low
25(OH)D levels will reverse these adverse processes and reduce
CVD risk [37]. Blood pressure reductions have been observed with
VitD supplementation [11,38], but the majority of studies have
shown no change [15,20,28]. Furthermore, 2 randomized
controlled trials showed no improvement in left ventricular
function in patients with heart failure randomized to VitD therapy
[39,40].
Although plausible biological mechanisms and epidemiological
data suggest that VitD deficiency may increase and VitD
supplementation may reduce CVD risk, observational studies
cannot account for unmeasured confounders. In our study, as in
others, individuals with low VitD tended to have a greater CVD
risk factor burden [5,8,10]. It has been proposed that low VitD is
responsible for these observations; however, it is possible that these
CVD risk factors simply are associated with lower 25(OH)D levels.
Indeed, previous studies have shown that the risk factors for VitD
deficiency are similar to traditional CVD risk factors [8]. In our
study, despite an average increase in circulating 25(OH)D levels of
nearly 16 ng/mL, we observed no improvements in FMD, PWV
or AIx, surrogate CVD risk markers that predict initial and
recurrent CVD events [14].
Limitations
Our endpoints are surrogate markers for CVD risk; we did not
evaluate CVD death, myocardial infarction, or stroke. Although
our markers are predictive of CVD events and are well-established
research tools, they are imperfect and an absence of change in
these measures does not exclude the possibility that VitD
supplementation may reduce CVD risk [14,17,41]. Participants
in this study were generally healthy post-menopausal women with
typical 25(OH)D levels. It is possible that VitD supplementation in
men or in individuals with higher baseline CVD risk or certain co-
morbidities, including abnormal endothelial function or lower
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the effects of VitD supplementation is challenged by the absence of
a widely accepted definition of vitamin D ‘‘insufficiency.’’
Proposed ‘‘reasonable’’ 25(OH)D levels range from 20 ng/mL
(50 nmol/L) to 32 ng/mL (80 nmol/L) [42,43] and some
advocate VitD supplementation in individuals with 25(OH)D
levels that are ,50 ng/mL [44]. Subjects in this study started with
a wide range of 25(OH)D levels; those subjects with higher starting
levels may have had a blunted arterial response to treatment
despite potentially being randomized to the treatment group.
Similarly, there is considerable debate regarding the optimal dose
for VitD supplementation and repletion in adults. Expert opinion
for supplemental dosing ranges from 600–1000 IU (20–25 mg) to
2000 IU (50 mg) daily [43,45,46], although some have argued that
even the latter dose may be inadequate and higher doses
frequently are used clinically [42]. Given the inconsistencies in
the literature, we cannot exclude the possibility that supplemen-
tation with even higher doses of VitD for a longer duration would
show a benefit in terms of CVD risk; however, interventions that
reduce CVD risk also tend to improve endothelial function and
arterial stiffness soon after initiating treatment, suggesting that
4 months was a reasonable duration of treatment [14,17,41].
Based on revised estimates using a mixed effects general linear
model and restricted maximum likelihood estimation, with
55 subjects per arm we had over 90% power to detect a 1.5%
difference in FMD. For PWV, we observed essentially no change
PWV and the SDs were very small, however there still is a small
chance that we missed a true difference between groups.
Conclusions
In the largest prospective randomized clinical trial of VitD
supplementation that used a dose of VitD that normalized VitD
levels in most participants, VitD supplementation did not improve
endothelial function, arterial stiffness, reduce CRP or improve
blood pressure in healthy, post-menopausal women. This study
does not support the use of VitD supplementation to reduce CVD
risk; however, long-term outcomes studies of this intervention are
needed.
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